ADA: American Diabetes Association – Page 3

Social Determinants of Physical Activity in Young Adults with and without Prediabetes or Type 2 Diabetes

This paper was presented as a part of the session “Physical Activity—Barriers, Facilitators, and Key Outcomes”on June 20th 2025 at the 85th ADA Scientific Sessions

Risks of Cancers among Novel Subtypes of Type 2 Diabetes—A Longitudinal Analysis from the United States

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Zhongyu Li

Longitudinal Trends in Diabetic Foot Ulcers and Lower Extremity Amputations before and after the COVID-19 Pandemic

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Ivan Y

Age at Type 2 Diabetes Diagnosis and Mortality and Cardiovascular Risks, and Years of Life Lost in South Asians

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Ayodipupo

The Significant Reduction in Epicardial Adipose Tissue Thickness after Dapagliflozin Treatment Is Preserved and Even Increased after Four Years—The DAPAHEART Four- Year Follow-up Study

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Cassaandra

Dapagliflozin Alters TCA Cycle Activation during Insulin Withdrawal in T1D Patients

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Samantha

A Four-Week Treatment with Dapagliflozin Reduces Insulin- Stimulated Renal Glucose Uptake

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Shawn

Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP- 1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single and Multiple Dose- Escalation Study

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Junfang

Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Jamy

Banting Medal Recipient Discusses Emerging Promise of Pharmacologic Treatment for Obesity And Diabetes

The approval of tirzepatide, the first dual incretin agonist, for the treatment of type 2 diabetes ushered in a “new era of metabolic medicine,” according